Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event
Preclinical Data Suggest IMM-1-104 May Offer Unique Therapeutic Advantage Compared with Binimetinib in NRAS Mutant Tumors Data to be discussed...